Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man

被引:19
|
作者
Becquemont, L
Camus, M
Eschwege, V
Barbu, V
Rey, E
Funck-Brentano, C
Jaillon, P
机构
[1] St Antoine Univ Hosp, Dept Pharmacol, F-75012 Paris, France
[2] Kremlin Bicetre Hosp, INSERM, U143, F-94275 Le Kremlin Bicetre, France
[3] St Antoine Univ Hosp, Dept Mol Biol, F-75012 Paris, France
[4] St Vincent de Paul Hosp, Dept Pharmacol, F-75014 Paris, France
[5] St Antoine Univ Hosp, AP HP, INSERM, Clin Invest Ctr, F-75012 Paris, France
关键词
P-glycoprotein; rifampicin; lymphocytes; human;
D O I
10.1111/j.1472-8206.2000.tb00435.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has recently been shown that P-glycoprotein (P-gp) is inducible by rifampicin in the human gut as shown in intestinal biopsies. The present study was performed in order to test the hypothesis that human peripheral lymphocytes can be used to assess such an inducibility. We also assessed inter- and intra-individual variability of P-gp expression and activity in peripheral lymphocytes. Blood samples from 13 healthy volunteers were collected 1, 7; 14 and 19 days after inclusion. Rifampicin treatment (600 mg/day) was administered from day 15 to day Is. Lymphocyte P-gp expression was measured at the messenger RNA level by semi-quantitative RT-PCR and at the protein level by immunostaining flow cytometry. P-gp activity was determined by flow cytometry with rhodamine 123 efflux. Cytochrome P4503A4 (CYP3A4) inducibility was measured by comparing the urinary metabolic ratio of 6 beta -hydroxycortisol/cortisol on day 14 and 19. Lymphocyte P-gp expression and activity was not induced by rifampicin, while it increased CYP3A4 activity from 5.0 +/- 4.0 to 22.9 +/- 16.6 (P < 0.001). There was a 3-4-fold inter-individual variability and a 3-44 % intra-individual variability of lymphocyte P-gp expression and activity. Peripheral lymphocytes are not an appropriate material to assess P-gp inducibility in humans. P-gp shows significant inter- and intra-individual variability in human lymphocytes. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:519 / 525
页数:7
相关论文
共 50 条
  • [31] P-GLYCOPROTEIN EXPRESSION IN ENDOMETRIAL CARCINOMA
    MONTEAGUDO, C
    MERINO, M
    AXIOTIS, C
    LABORATORY INVESTIGATION, 1990, 62 (01) : A69 - A69
  • [33] SPECIFICITY OF IMMUNOHISTOCHEMICAL EXPRESSION OF P-GLYCOPROTEIN
    BATTIFORA, H
    HUMAN PATHOLOGY, 1991, 22 (05) : 506 - 506
  • [34] P-glycoprotein expression in cartilaginous tumors
    Rosier, RN
    OKeefe, RJ
    Teot, LA
    Fox, EJ
    Nester, TA
    Puzas, JE
    Reynolds, PR
    Hicks, DG
    JOURNAL OF SURGICAL ONCOLOGY, 1997, 65 (02) : 95 - 105
  • [35] Chemotherapy and P-glycoprotein expression in chondrosarcoma
    Terek, RM
    Schwartz, GK
    Devaney, K
    Glantz, L
    Mak, S
    Healey, JH
    Albino, AP
    JOURNAL OF ORTHOPAEDIC RESEARCH, 1998, 16 (05) : 585 - 590
  • [36] Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin
    Guo, Mengjie
    Dai, Xiaohua
    Hu, Dongmin
    Zhang, Yu
    Sun, Yong
    Ren, Weilong
    Wang, Liping
    POULTRY SCIENCE, 2016, 95 (09) : 2129 - 2135
  • [37] Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein
    Lecoeur, S
    Videmann, B
    Mazallon, M
    TOXICOLOGY LETTERS, 2006, 161 (03) : 200 - 209
  • [38] Modulation of P-glycoprotein expression/activity in HK2 cells
    Matos, J. V.
    Morales, A.
    Silva, R.
    Remiao, F.
    Prieto, M.
    TOXICOLOGY LETTERS, 2021, 350 : S94 - S94
  • [39] Colchicine effect on P-glycoprotein expression and activity: In silico and in vitro studies
    Silva, Renata
    Carmo, Helena
    Viras-Boas, Vania
    Barbosa, Daniel Jose
    Palmeira, Andreia
    Sousa, Emilia
    Carvalho, Felix
    Bastos, Maria de Lourdes
    Remiao, Fernando
    CHEMICO-BIOLOGICAL INTERACTIONS, 2014, 218 : 50 - 62
  • [40] Absence of induction of the P-glycoprotein in human lymphocytes by rifampicin, phenobarbital and efavirenz
    Giraud, C.
    Manceau, S.
    Decleves, X.
    Batteux, F.
    Chouzenoux, S.
    Tang, R.
    Dauchy, S.
    Scherrmann, J. M.
    Weill, B.
    Morini, J. P.
    Perrot, J. Y.
    Treluyer, J. M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 68 - 69